Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson's disease and controls

Behavioural Brain Research

Volumn 233, Issue 1, 2012, Pages 15-23

  Riddle, J L ^a   Rokosik, S L ^a,b   Napier, T C ^a  

^a Center for Compulsive Behavior and Addiction   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

6 OHDA; Conditioned place preference; Methamphetamine; Motor; Pramipexole; Reward

Indexed keywords

METHAMPHETAMINE; OXIDOPAMINE; PRAMIPEXOLE; SODIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DOSE COMPARISON; DRUG MECHANISM; EXPERIMENTAL TEST; FORELIMB ADJUSTING STEP TEST; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; REWARD; SHAM PROCEDURE;

ADRENERGIC AGENTS; ANALYSIS OF VARIANCE; ANIMALS; ASSOCIATION LEARNING; BENZOTHIAZOLES; CONDITIONING, OPERANT; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FORELIMB; MALE; METHAMPHETAMINE; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; OXIDOPAMINE; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; RATS; RATS, SPRAGUE-DAWLEY; REWARD; TYROSINE 3-MONOOXYGENASE;

EID: 84861541185     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.04.027     Document Type: Article

References (90)

1. Abler B., Hahlbrock R., Unrath A., Gron G., Kassubek J. At-risk for pathological gambling: imaging neural reward processing under chronic dopamine agonists. Brain 2009, 132:2396-2402.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th text revisioned, Washington, DC: 2000.
3. Baracz S.J., Rourke P.I., Pardey M.C., Hunt G.E., McGregor I.S., Cornish J.L. Oxytocin directly administered into the nucleus accumbens core or subthalamic nucleus attenuates methamphetamine-induced conditioned place preference. Behavioural Brain Research 2011, 228:185-193.
4. Bearn J., Evans A., Kelleher M., Turner K., Lees A. Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study. Drug and Alcohol Dependence 2004, 76:305-310.
5. Bennett J.P., Piercey M.F. Pramipexole - a new dopamine agonist for the treatment of Parkinson's disease. Journal of the Neurological Sciences 1999, 163:25-31.
6. Bodi N., Keri S., Nagy H., Moustafa A., Myers C.E., Daw N., Dibo G., Takats A., Bereczki D., Gluck M.A. Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patients. Brain 2009, 132:2385-2395.
7. Bradley V.A., Welch J.L., Dick D.J. Visuospatial working memory in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 1989, 52:1228-1235.
8. 3 receptor test in vitro predicts decreased cocaine self- administration in rats. Neuroreport 1997, 8:2373-2377.
9. Cervenka S., Palhagen S.E., Comley R.A., Panagiotidis G., Cselenyi Z., Matthews J.C., Lai R.Y., Halldin C., Farde L. Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain 2006, 129:2017-2028.
10. Chang J.W., Wachtel S.R., Young D., Kang U.J. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 1999, 88:617-628.
11. Chang W.L., Breier M.R., Yang A., Swerdlow N.R. Disparate effects of pramipexole on locomotor activity and sensorimotor gating in Sprague-Dawley rats. Pharmacology Biochemistry and Behavior 2011, 99:634-638.
12. Chaperon F., Thiébot M.H. Effects of dopaminergic D3-receptor-preferring ligands on the acquisition of place conditioning in rats. Behavioural Pharmacology 1996, 7:105-109.
13. Collins G.T., Cunningham A.R., Chen J., Wang S., Newman A.H., Woods J.H. Effects of pramipexole on the reinforcing effectiveness of stimuli that were previously paired with cocaine reinforcement in rats. Psychopharmacology 2012, 219(1):123-135.
14. Collins G.T., Newman A.H., Grundt P., Rice K.C., Husbands S.M., Chauvignac C., Chen J., Wang S., Woods J.H. Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology 2007, 193:159-170.
15. Collins G.T., Witkin J.M., Newman A.H., Svensson K.A., Grundt P., Cao J., Woods J.H. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. Journal of Pharmacology and Experimental Therapeutics 2005, 314:310-319.
16. Cooper J.A., Sagar H.J., Jordan N., Harvey N.S., Sullivan E.V. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 1991, 114:2095-2122.
17. Cox S.M., Stefanova E., Johnsrude I.S., Robbins T.W., Owen A.M. Preference formation and working memory in Parkinson's disease and normal ageing. Neuropsychologia 2002, 40:317-326.
18. Cunningham C.L., Ferree N.K., Howard M.A. Apparatus bias and place conditioning with ethanol in mice. Psychopharmacology 2003, 170:409-422.
19. d'Orsi G., Demaio V., Specchio L.M. Pathological gambling plus hypersexuality in restless legs syndrome: a new case. Neurological Sciences 2011, 32:707-709.
20. Deumens R., Blokland A., Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Experimental Neurology 2002, 175:303-317.
21. Dooley M., Pramipexole M.A. A review of its use in the management of early and advanced Parkinson's disease. Drugs and Aging 1998, 12:495-514.
22. Earley C.J., Kuwabara H., Wong D.F., Gamaldo C., Salas R., Brasic J., Ravert H.T., Dannals R.F., Allen R.P. The dopamine transporter is decreased in the striatum of subjects with restless legs syndrome. Sleep 2011, 34:341-347.
23. Etminan M., Gill S., Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Drug Safety 2003, 26:439-444.
24. Evans A.H., Lawrence A.D., Cresswell S.A., Katzenschlager R., Lees A.J. Compulsive use of dopaminergic drug therapy in Parkinson's disease: reward and anti-reward. Movement Disorders 2010, 25:867-876.
25. Evans A.H., Strafella A.P., Weintraub D., Stacy M. Impulsive and compulsive behaviors in Parkinson's disease. Movement Disorders 2009, 24:1561-1570.
26. Everitt B.J., Morris K.A., O'Brien A., Robbins T.W. The basolateral amygdala-ventral striatal system and conditioned place preference: further evidence of limbic-striatal interactions underlying reward-related processes. Neuroscience 1991, 42:1-18.
27. Featherstone R.E., McDonald R.J. Dorsal striatum and stimulus-response learning: lesions of the dorsolateral, but not dorsomedial, striatum impair acquisition of a stimulus-response-based instrumental discrimination task, while sparing conditioned place preference learning. Neuroscience 2004, 124:23-31.
28. Featherstone R.E., McDonald R.J. Lesions of the dorsolateral or dorsomedial striatum impair performance of a previously acquired simple discrimination task. Neurobiology of Learning and Memory 2005, 84:159-167.
29. Ferro M.M., Bellissimo M.I., Anselmo-Franci J.A., Angellucci M.E., Canteras N.S., Da C.C. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. Journal of Neuroscience Methods 2005, 148:78-87.
30. Fricks-Gleason A.N., Khalaj A.J., Marshall J.F. Dopamine D1 receptor antagonism impairs extinction of cocaine-cue memories. Behavioural Brain Research 2012, 226:357-360.
31. Giovannoni G., O'Sullivan J.D., Turner K., Manson A.J., Lees A.J. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. Journal of Neurology, Neurosurgery and Psychiatry 2000, 68:423-428.
32. Grant J.E., Potenza M.N., Weinstein A., Gorelick D.A. Introduction to behavioral addictions. American Journal of Drug and Alcohol Abuse 2010, 36:233-241.
33. Gyertyan I., Gal K. Dopamine D3 receptor ligands show place conditioning effect but do not influence cocaine-induced place preference. Neuroreport 2003, 14:93-98.
34. Hamidovic A., Kang U.J., de Wit H. Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. Journal of Clinical Psychopharmacology 2008, 28:45-51.
35. Hauser R.A., Gauger L., Anderson W.M., Zesiewicz T.A. Pramipexole-induced somnolence and episodes of daytime sleep. Movement Disorders 2000, 15:658-663.
36. Hemby S.E., Jones G.H., Justice J.B., Neill D.B. Conditioned locomotor activity but not conditioned place preference following intra-accumbens infusions of cocaine. Psychopharmacology 1992, 106:330-336.
37. Herrold A.A., Shen F., Graham M.P., Harper L.K., Specio S.E., Tedford C.E., Napier T.C. Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug and Alcohol Dependence 2009, 99:231-239.
38. Herrold A.A., Voigt R.M., Napier T.C. Brain region selective cellular redistribution of mGlu5 but not GABA(B) receptors following methamphetamine-induced associative learning. Synapse 2011, 65:1333-1343.
39. Hobson D.E., Pourcher E., Martin W.R. Ropinirole and pramipexole, the new agonists. Canadian Journal of Neurological Sciences 1999, 26(Suppl. 2):S27-S33.
40. Hoffman D.C., Dickson P.R., Beninger R.J. The dopamine D2 receptor agonists, quinpirole and bromocriptine produce conditioned place preferences. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1988, 12:315-322.
41. Holman A.J. Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia. Journal of Gambling Studies 2009, 25:425-431.
42. Horstink M., Tolosa E., Bonuccelli U., Deuschl G., Friedman A., Kanovsky P., Larsen J.P., Lees A., Oertel W., Poewe W., Rascol O., Sampaio C. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. European Journal of Neurology 2006, 13:1170-1185.
43. Johnson P.S., Madden G.J., Brewer A.T., Pinkston J.W., Fowler S.C. Effects of acute pramipexole on preference for gambling-like schedules of reinforcement in rats. Psychopharmacology 2011, 231:11-18.
44. Khroyan T.V., Baker D.A., Fuchs R.A., Manders N., Neisewander J.L. Differential effects of 7-OH-DPAT on amphetamine-induced stereotypy and conditioned place preference. Psychopharmacology 1998, 139:332-341.
45. 3-preferring agonist 7-OH-DPAT on motor behaviors and place conditioning. Psychopharmacology 1995, 122:351-357.
46. Khroyan T.V., Fuchs R.A., Baker D.A., Neisewander J.L. Effects of D3-preferring agonists 7-OH-PIPAT and PD-128,907 on motor behaviors and place conditioning. Behavioural Pharmacology 1997, 8:65-74.
47. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. New England Journal of Medicine 1988, 318:876-880.
48. Koffarnus M.N., Newman A.H., Grundt P., Rice K.C., Woods J.H. Effects of selective dopaminergic compounds on a delay-discounting task. Behavioural Pharmacology 2011, 22:300-311.
49. Lagos P., Scorza C., Monti J.M., Jantos H., Reyes-Parada M., Silveira R., Ponzoni A. Effects of the D3 preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats. European Neuropsychopharmacology 1998, 8:113-120.
50. Lawrence A.D., Evans A.H., Lees A.J. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry. Lancet Neurology 2003, 2:595-604.
51. Leu-Semenescu S., Karroum E., Brion A., Konofal E., Arnulf I. Dopamine dysregulation syndrome in a patient with restless legs syndrome. Sleep Medicine 2009, 10:494-496.
52. Lin K.Y., Cherng C.G., Yang F.R., Lin L.C., Lu R.B., Yu L. Memantine abolishes the formation of cocaine-induced conditioned place preference possibly via its IL-6-modulating effect in medial prefrontal cortex. Behavioural Brain Research 2011, 220:126-131.
53. Madden G.J., Johnson P.S., Brewer A.T., Pinkston J.W., Fowler S.C. Effects of pramipexole on impulsive choice in male Wistar rats. Experimental and Clinical Psychopharmacology 2010, 18:267-276.
54. Maj J., Rogoz Z., Skuza G., Kolodziejczyk K. The behavioural effects of pramipexole, a novel dopamine receptor agonist. European Journal of Pharmacology 1997, 324:31-37.
55. Mallet P.E., Beninger R.J. 7-OH-DPAT produces place conditioning in rats. European Journal of Pharmacology 1994, 261:R5-R6.
56. McDaid J., Graham M.P., Napier T.C. Methamphetamine-induced sensitization differentially alters pCREB and ΔFosB throughtout the limbic circuit of the mammalian brain. Molecular Pharmacology 2006, 70:2064-2074.
57. Micallef J., Rey M., Eusebio A., Audebert C., Rouby F., Jouve E., Tardieu S., Blin O. Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects. British Journal of Clinical Pharmacology 2009, 67:333-340.
58. Miyasaki J.M., Martin W., Suchowersky O., Weiner W.J., Lang A.E. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002, 58:11-17.
59. Molina J.A., Sainz-Artiga M.J., Fraile A., Jimenez-Jimenez F.J., Villanueva C., Orti-Pareja M., Bermejo F. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment. Movement Disorders 2000, 15:869-872.
60. Nikolaus S., Antke C., Muller H.W. In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. Behavioural Brain Research 2009, 204:32-66.
61. O'Suilleabhain P.E., Dewey R.B. Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease. Archives of Neurology 2002, 59:986-989.
62. O'Sullivan S.S., Evans A.H., Lees A.J. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 2009, 23:157-170.
63. Olmstead M.C., Franklin K.B.J. Lesions of the pedunculopontine tegmental nucleus block drug-induced reinforcement but not amphetamine-induced locomotion. Brain Research 1994, 638:29-35.
64. Olsson M., Nikkhah G., Bentlage C., Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. Journal of Neuroscience 1995, 15:3863-3875.
65. Pizzagalli D.A., Evins A.E., Schetter E.C., Frank M.J., Pajtas P.E., Santesso D.L., Culhane M. Single dose of a dopamine agonist impairs reinforcement learning in humans: behavioral evidence from a laboratory-based measure of reward responsiveness. Psychopharmacology 2008, 196:221-232.
66. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., Togasaki D.M. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 1995, 67:631-647.
67. Quickfall J., Suchowersky O. Pathological gambling associated with dopamine agonist use in restless legs syndrome. Parkinsonism & Related Disorders 2007, 13:535-536.
68. Rabinak C.A., Nirenberg M.J. Dopamine agonist withdrawal syndrome in Parkinson disease. Archives of Neurology 2010, 67:58-63.
69. Reichmann H., Brecht M.H., Koster J., Kraus P.H., Lemke M.R. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease. CNS Drugs 2003, 17:965-973.
70. Riba J., Kramer U.M., Heldmann M., Richter S., Munte T.F. Dopamine agonist increases risk taking but blunts reward-related brain activity. PLoS ONE 2008, 3:e2479.
71. Richtand N.M. Behavioral sensitization, alternative splicing, and d3 dopamine receptor-mediated inhibitory function. Neuropsychopharmacology 2006, 31:2368-2375.
72. Richtand N.M., Woods S.C., Berger S.P., Strakowski S.M. D3 dopamine receptor, behavioral sensitization, and psychosis. Neuroscience and Biobehavioral Reviews 2001, 25:427-443.
73. Rokosik S., Napier T.C. Pramipexole-induced increased probabilistic discounting: comparison between a rodent model of Parkinson's disease and controls. Neuropsychopharmacology 2012, 37(6):1397-1408.
74. Samuels E.R., Hou R.H., Langley R.W., Szabadi E., Bradshaw C.M. Comparison of pramipexole and amisulpride on alertness, autonomic and endocrine functions in healthy volunteers. Psychopharmacology 2006, 187:498-510.
75. Samuels E.R., Hou R.H., Langley R.W., Szabadi E., Bradshaw C.M. Comparison of pramipexole and modafinil on arousal, autonomic, and endocrine functions in healthy volunteers. Journal of Psychopharmacology 2006, 20:756-770.
76. Santesso D.L., Evins A.E., Frank M.J., Schetter E.C., Bogdan R., Pizzagalli D.A. Single dose of a dopamine agonist impairs reinforcement learning in humans: evidence from event-related potentials and computational modeling of striatal-cortical function. Human Brain Mapping 2009, 30:1963-1976.
77. Seedat S., Kesler S., Niehaus D.J., Stein D.J. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depression and Anxiety 2000, 11:185-186.
78. Shen F., Meredith G.E., Napier T.C. Amphetamine-induced place preference and conditioned motor sensitization requires activation of tyrosine kinase receptors in the hippocampus. Journal of Neuroscience 2006, 26:11041-11051.
79. Stahl S.M. Fibromyalgia - pathways and neurotransmitters. Human Psychopharmacology 2009, 24(Suppl. 1):S11-S17.
80. Strejilevich S.A., Martino D.J., Igoa A., Manes F. Pathological gambling in a bipolar patient treated with pramipexole. Journal of Neuropsychiatry and Clinical Neurosciences 2011, 23:E2-E3.
81. Swanson C.J., Heath S., Stratford T.R., Kelley A.E. Differential behavioral responses to dopaminergic stimulation of nucleus accumbens subregions in the rat. Pharmacology Biochemistry & Behavior 1997, 58:933-945.
82. Tippmann-Peikert M., Park J.G., Boeve B.F., Shepard J.W., Silber M.H. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007, 68:301-303.
83. Todes C.J., Lees A.J. The pre-morbid personality of patients with Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 1985, 48:97-100.
84. Voigt R.M., Herrold A.A., Napier T.C. Baclofen facilitates the extinction of methamphetamine-induced conditioned place preference in rats. Behavioral Neuroscience 2011, 125:261-267.
85. Voigt R.M., Herrold A.A., Riddle J.L., Napier T.C. Administration of GABA(B) receptor positive allosteric modulators inhibit the expression of previously established methamphetamine-induced conditioned place preference. Behavioural Brain Research 2011, 216:419-423.
86. Weintraub D., Koester J., Potenza M.N., Siderowf A.D., Stacy M., Voon V., Whetteckey J., Wunderlich G.R., Lang A.E. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Archives of Neurology 2010, 67:589-595.
87. Wiener S.I. Spatial and behavioral correlates of striatal neurons in rats performing a self-initiated navigation task. Journal of Neuroscience 1993, 13:3802-3817.
88. Yang M.H., Kim S., Jung M.S., Shim J.H., Ryu N.K., Yook Y.J., Jang C.G., Bahk Y.Y., Kim K.W., Park J.H. Proteomic analysis of methamphetamine-induced reinforcement processes within the mesolimbic dopamine system. Addiction Biology 2008, 13:287-294.
89. Ye Z., Hammer A., Camara E., Munte T.F. Pramipexole modulates the neural network of reward anticipation. Human Brain Mapping 2011, 32:800-811.
90. Ziemssen T., Reichmann H. Non-motor dysfunction in Parkinson's disease. Parkinsonism & Related Disorders 2007, 13:323-332.